Uwe Himmelreich (°1965) has studied physical chemistry. He has more than 25 years of research experience in magnetic resonance imaging and spectroscopy. He is the coordinator of the KU Leuven core facility MoSAIC with approximately 150 users. He is currently the promoter of 9 PhD students. His expertise is in the development of novel, multi-modal in vivo imaging approaches in preclinical research. Hereby, the focus is on the non-invasive characterization of experimental disease and treatment models, including in neurodegeneration (Alzheimer’s, Parkinson’s disease, ALS), infectious diseases (fungal infections) and oncology. He has a strong interest in the development and validation of new contrast agents for in vivo cell imaging and potential theranostic applications. This includes nanoparticles for the validation of novel approaches in treatment monitoring and nanoparticles for theranostic applications. Hereby, he tries to combine different imaging modalities (MRI, PET, CT, OI) to overcome limitations of individual methods. He has published more than 200 papers in peer-reviewed journals.
The Biomedical MRI at the KU Leuven core facility MoSAIC focuses on the in vivo characterization of experimental disease and treatment models. Hereby, we make use of all state-of-the-art in vivo imaging modalities. Our infrastructure includes a 9.4T MRI scanner (Bruker Biospec), a PET scanner (Focus 220), a 7T PET/ MRI scanner (Bruker Biospec/ Albeira) CT scanners (Skyscan 1076 and Skyscan 1278), ultrasound scanners (Visualsonics), optical imaging instrumentation (IVIS Spectrum from Perkin Elmer, IVM from Cellvizio and OCT from AGFA), phase contrast imaging (Carestream) and others. Matching clinical infrastructure is available as we are based on the campus of the University Hospital Leuven. Our research also involves the development and validation of contrast agents (mainly nanoparticles) and tracers (GMP cyclotron on campus).